Conversely, transient application of HMG-CoA reductase inhibitor Simvastatin or the farnesyl diphosphate synthase (FPPS) inhibitor Zoledronic acid significantly decreased brain infarction volume in MCAO (Fig 7I and 7J). Here, HMGCR is linked to brain infarction.